ClinicalTrials.gg
Status unknownNCT02518789Updated Aug 10, 2015

Effects and Mechanism of Pretreatment With Dexmedetomidine to Etomidate Induce Myoclonus

A Phase 4 interventional study of Low-dose Dexmedetomidine and High-dose dexmedetomidine in Myoclonus, sponsored by Tang-Du Hospital. Status unknown. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2015-08-10.

Sponsored by Tang-Du Hospital · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2015), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Phase 4
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

By observing the difference of plasma homovanillic acid concentrations and brain electrical consciousness monitoring Narcotrend index, study the possible mechanism of influencing Etomidate induced myoclonus with Dexmedetomidine pretreatment during general anesthesia induction period.

02

Conditions studied

  • Myoclonus

Browse trials for

Keywords

  • myoclonus
  • Etomidate
  • Dexmedetomidine
03

In context

Myoclonus

20 studies on the registry are indexed under Myoclonus; 6 are open to participants now.

This study's planned enrollment of 132 is above the median of 50 across 11 interventional studies indexed under Myoclonus.

Browse Myoclonus studies →

Lead sponsor

Tang-Du Hospital is the lead sponsor of 167 studies on the registry; 78 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sign the
  • (ASA)classification:class I\~II;undergoing elective surgery patients
  • Aged between 18 and 55, 49-67 kg weight
  • (BMI): 20-30 kg/m2
  • Did not use any analgesic or sedatives drugs within 24 h pre-operation

Exclusion criteria

Exclusion Criteria:

  • Recently patients undergoing sedative drugs and antidepressant treatment
  • Serious vision, hearing impairment or other reasons can not communicate
  • Serious neurological disease, pregnancy, diseases of the cardiovascular system;
  • is Less than the standard 80% or higher than the standard 120%
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
132 participants (estimated)

Study arms

  • Experimental
    Low-dose Dexmedetomidine

    -Pretreatment before anesthesia induction:Intravenous injection dexmedetomidine 0.5 µg/kg,completed within 15 minutes.

    Drug: Low-dose Dexmedetomidine · Drug: Etomidate · Drug: midazolam,fentanyl,rocuronium · Drug: propofol,remifentanil,cis atracurium

  • Experimental
    High-dose Dexmedetomidine

    -Pretreatment before anesthesia induction:Intravenous injection dexmedetomidine 1 µg/kg,completed within 15 minutes.

    Drug: High-dose dexmedetomidine · Drug: Etomidate · Drug: midazolam,fentanyl,rocuronium · Drug: propofol,remifentanil,cis atracurium

  • Placebo comparator
    normal saline Control group

    -Pretreatment before anesthesia induction:Intravenous injection normal saline equal quantity,completed within 15 minutes.

    Drug: normal saline · Drug: Etomidate · Drug: midazolam,fentanyl,rocuronium · Drug: propofol,remifentanil,cis atracurium

Interventions

  • Pretreatment:Intravenous injection dexmedetomidine 0.5 µg/kg ,completed within 15 minutes.

    Also known as: Yisi

  • Pretreatment:Intravenous injection dexmedetomidine 1 µg/kg ,completed within 15 minutes.

    Also known as: Yisi

  • Drugnormal saline

    Pretreatment:Intravenous injection normal saline equal quantity,completed within 15 minutes.

    Also known as: Sodium Chloride Physiological Solution

  • After 90 seconds of Pretreatment,intravenous infusion of etomidate fat emulsion 0.3mg/kg. -Does not offer any other drugs within 5 min after completion of etomidate.

    Also known as: Fuerli

  • Drugmidazolam,fentanyl,rocuronium

    Anesthesia induction:Intravenous injection midazolam 0.03 \~ 0.05 mg/kg, fentanyl 5 \~ 8 g/kg, rocuronium 0.6 mg/kg

    Also known as: Liyuexi,Fentanyl Citrate Injection,Aikesong

  • Drugpropofol,remifentanil,cis atracurium

    Anesthesia maintenance:Intravenous infusion of propofol 4 \~ 6 mg/kg/h, remifentanil 0.1 \~ 0.3 μg/kg/min, intermittent intravenous injection of cis atracurium 0.05 \~ 0.1mg/kg

    Also known as: Propofol Injection,Ruifen,Cisatracurium Besylate Injection

06

What researchers measure

Primary outcomes

  1. myoclonus level

    * Level 0 :no myoclonus happened; * Level 1 :mild, tiny movement, one part of the body such as a finger or shoulder movement; * Level 2 :moderate ,2 pieces of different muscle or slight movement of the muscle groups, such as face or legs; * Level 3 :severely, 2 pieces or more muscle contracture intensity, such as fast outreach of limbs

    Time frame: when myoclonus occurs after emulsion injection is completed,assessed up to 5 minutes

  2. Plasma homovanillic acid concentration(PHVA)

    Time frame: Measured when myoclonus occurs after emulsion injection is completed,assessed up to 5 minutes; if myoclonus does not appear,measured at 5 minutes after emulsion injection is completed.

Secondary outcomes

  1. Ramsay sedation score

    Time frame: 1 min after entering the operating room; 1 min after dexmedetomidine injection is completed; 1 min after emulsion injection is completed;5 minutes after emulsion injection is completed;

  2. Narcotrend index

    Time frame: 1 min after entering the operating room; 1 min after dexmedetomidine injection is completed; 1 min after emulsion injection is completed;5 minutes after emulsion injection is completed;

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Schwarzkopf KR, Hueter L, Simon M, Fritz HG. Midazolam pretreatment reduces etomidate-induced myoclonic movements. Anaesth Intensive Care. 2003 Feb;31(1):18-20. doi: 10.1177/0310057X0303100103. PubMed 12635389 ↗
  • Stockham RJ, Stanley TH, Pace NL, Gillmor S, Groen F, Hilkens P. Fentanyl pretreatment modifies anaesthetic induction with etomidate. Anaesth Intensive Care. 1988 May;16(2):171-6. doi: 10.1177/0310057X8801600207. PubMed 3394909 ↗
  • Doenicke AW, Roizen MF, Kugler J, Kroll H, Foss J, Ostwald P. Reducing myoclonus after etomidate. Anesthesiology. 1999 Jan;90(1):113-9. doi: 10.1097/00000542-199901000-00017. PubMed 9915320 ↗
  • Paris A, Philipp M, Tonner PH, Steinfath M, Lohse M, Scholz J, Hein L. Activation of alpha 2B-adrenoceptors mediates the cardiovascular effects of etomidate. Anesthesiology. 2003 Oct;99(4):889-95. doi: 10.1097/00000542-200310000-00022. PubMed 14508322 ↗
  • Maze M, Virtanen R, Daunt D, Banks SJ, Stover EP, Feldman D. Effects of dexmedetomidine, a novel imidazole sedative-anesthetic agent, on adrenal steroidogenesis: in vivo and in vitro studies. Anesth Analg. 1991 Aug;73(2):204-8. doi: 10.1213/00000539-199108000-00015. PubMed 1649559 ↗
  • Venn RM, Bryant A, Hall GM, Grounds RM. Effects of dexmedetomidine on adrenocortical function, and the cardiovascular, endocrine and inflammatory responses in post-operative patients needing sedation in the intensive care unit. Br J Anaesth. 2001 May;86(5):650-6. doi: 10.1093/bja/86.5.650. PubMed 11575340 ↗
  • Mizrak A, Koruk S, Bilgi M, Kocamer B, Erkutlu I, Ganidagli S, Oner U. Pretreatment with dexmedetomidine or thiopental decreases myoclonus after etomidate: a randomized, double-blind controlled trial. J Surg Res. 2010 Mar;159(1):e11-6. doi: 10.1016/j.jss.2009.07.031. Epub 2009 Aug 19. PubMed 20018300 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2015, a primary completion of Aug 2016 and a completion of Sep 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2015
First posted
Aug 10, 2015
Start
Sep 2015
Primary completionEst.
Aug 2016
CompletionEst.
Sep 2016
Last update
Aug 10, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02518789
Lead sponsor
Tang-Du Hospital
Responsible party
Sponsor
First posted
Aug 10, 2015
Start date
Sep 2015
Primary completion
Aug 2016 (estimated)
Completion
Sep 2016 (estimated)
Last update
Aug 10, 2015

Study contacts

LI yumin, PHD
principal investigator · Air Force Military Medical University, China

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion